Avenue Therapeutics (NASDAQ:ATXI) Stock Price Up 4.9% – Should You Buy?

Shares of Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) rose 4.9% during trading on Tuesday. The stock traded as high as $0.4403 and last traded at $0.42. Approximately 3,036 shares changed hands during trading, a decline of 55% from the average session volume of 6,771 shares. The stock had previously closed at $0.4005.

Avenue Therapeutics Stock Up 4.9%

The stock’s 50-day moving average is $0.43 and its 200 day moving average is $0.39. The stock has a market capitalization of $1.38 million, a PE ratio of 0.02 and a beta of -0.23.

About Avenue Therapeutics

(Get Free Report)

Avenue Therapeutics, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for acute and other serious medical conditions. The company is headquartered in the United States and trades on the Nasdaq under the symbol ATXI.

Avenue’s primary product candidate has been intravenous tramadol, an investigational formulation intended to provide short-term management of acute postoperative pain in adults who require an opioid analgesic in a medically supervised setting.

Featured Articles

• Five stocks we like better than Avenue Therapeutics
• A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
• Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
• Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
• Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs